Trial · NCT07883044
Microencapsulated Sodium Propionate in IBD Microbiota Modulation
NCT07883044, Not applicable, Recruiting, University of Padova
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Microencapsulated Sodium Propionate in IBD Microbiota Modulation. Trials, record NCT07883044. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883044
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Microencapsulated Sodium Propionate in IBD Microbiota Modulation
- NCT number
- NCT07883044
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- University of Padova
- Conditions
- Crohn Disease
- Interventions
- Microencapsulated sodium propiolate, Microencapsulated sodium Butyrate
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Gut Microbiota Composition | At baseline; at the first 45-day treatment period, and at the end of the second 45-day treatment period following crossover and washout (up to 15 weeks). | Assessment of changes in gut microbiota composition and diversity, |
| Secondary | Change in metabolic pathway | At baseline; at the first 45-day treatment period, and at the end of the second 45-day treatment period following crossover and washout (up to 15 weeks). | Shotgun metagenomic analysis of fecal samples collected at predefined time points. |
| Secondary | Changes in Inflammatory Markers | At baseline, after the first 45-day treatment period, and at the end of the second 45-day treatment period following crossover and washout (up to 15 weeks). | Evaluation of the effects of sodium propionate compared to sodium butyrate on inflammatory cytokines (IL-17, IFN-γ, IL-10), |
| Secondary | Changes in Immune Cell Modulation | At baseline, after the first 45-day treatment period, and at the end of the second 45-day treatment period following crossover and washout (up to 15 weeks). | Evaluation of the effects of sodium propionate compared to sodium butyrate on immune regulation through modulation of Treg and Th17 cell activity, |
| Secondary | Changes in Quality of Life | At baseline, after the first 45-day treatment period, and at the end of the second 45-day treatment period following crossover and washout (up to 15 weeks). | Evaluation of the effects of sodium propionate compared to sodium butyrate on patient-reported quality of life measured by the IBDQ questionnaire at predefined time points ( score 32-224, \>170 good QoL) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883044
GET https://conductscience.org/api/trials/v1/NCT07883044/registered